|
1
|
Mattiuzzi C and Lippi G: Current cancer
epidemiology. J Epidemiol Glob Health. 9:217–22. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bach PB: Smoking as a factor in causing
lung cancer. JAMA. 301:539–541. 2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gregg JP, Li T and Yoneda KY: Molecular
testing strategies in non-small cell lung cancer: Optimizing the
diagnostic journey. Transl Lung Cancer Res. 8:286–301.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lu F, Li S, Dong B, Zhang S, Lv C and Yang
Y: Identification of lung adenocarcinoma mutation status based on
histologic subtype: Retrospective analysis of 269 patients. Thorac
Cancer. 7:17–23. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Yang H, Jiang P, Liu D, Wang HQ, Deng Q,
Niu X, Lu L, Dai H, Wang H and Yang W: Matrix metalloproteinase 11
is a potential therapeutic target in lung adenocarcinoma. Mol Ther
Oncolytics. 14:82–93. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chen YJ, Roumeliotis TI, Chang YH, Chen
CT, Han CL, Lin MH, Chen HW, Chang GC, Chang YL, Wu CT, et al:
Proteogenomics of non-smoking lung cancer in East Asia delineates
molecular signatures of pathogenesis and progression. Cell.
182:226–244.e17. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Paver E, O'Toole S, Cheng XM, Mahar A and
Cooper WA: Updates in the molecular pathology of non-small cell
lung cancer. Semin Diagn Pathol. 38:54–61. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yu H, Boyle TA, Zhou C, Rimm DL and Hirsch
FR: PD-L1 expression in lung cancer. J Thorac Oncol. 11:964–975.
2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gu Y, Tang YY, Wan JX, Zou JY, Lu CG, Zhu
HS, Sheng SY, Wang YF, Liu HC, Yang J and Hong H: Sex difference in
the expression of PD-1 of non-small cell lung cancer. Front
Immunol. 13(1026214)2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Jazieh AR, Jaafar H, Jaloudi M, Mustafa
RS, Rasul K, Zekri J, Bamefleh H and Gasmelseed A: Patterns of
epidermal growth factor receptor mutation in non-small-cell lung
cancers in the Gulf region. Mol Clin Oncol. 3:1371–1374.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Fakhruddin N, Mahfouz R, Farhat F, Tfayli
A, Abdelkhalik R, Jabbour M, Yehia L, Mahfoud Z and Zaatari G:
Epidermal growth factor receptor and KRAS mutations in lung
adenocarcinoma: A retrospective study of the Lebanese population.
Oncol Rep. 32:2223–2229. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Shi Y, Au JSK, Thongprasert S, Srinivasan
S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A
prospective, molecular epidemiology study of EGFR mutations in
Asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Melosky B, Kambartel K, Häntschel M,
Bennetts M, Nickens DJ, Brinkmann J, Kayser A, Moran M and Cappuzzo
F: Worldwide prevalence of epidermal growth factor receptor
mutations in non-small cell lung cancer: A meta-analysis. Mol Diagn
Ther. 26:7–18. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jurišić V, Obradovic J, Pavlović S and
Djordjevic N: Epidermal growth factor receptor gene in
non-small-cell lung cancer: The importance of promoter polymorphism
investigation. Anal Cell Pathol (Amst).
2018(6192187)2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tanaka T, Matsuoka M, Sutani A, Gemma A,
Maemondo M, Inoue A, Okinaga S, Nagashima M, Oizumi S, Uematsu K,
et al: Frequency of and variables associated with the EGFR mutation
and its subtypes. Int J Cancer. 126:651–655. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Boustany Y, Laraqui A, El Rhaffouli H,
Bajjou T, El Mchichi B, El Anaz H, Amine IL, Chahdi H, Oukabli M,
Souhi H, et al: Prevalence and patterns of EGFR mutations in
non-small cell lung cancer in the Middle East and North Africa.
Cancer Control. 29(10732748221129464)2022.
|
|
17
|
Tseng CH, Chiang CJ, Tseng JS, Yang TY,
Hsu KH, Chen KC, Wang CL, Chen CY, Yen SH, Tsai CM, et al: EGFR
mutation, smoking, and gender in advanced lung adenocarcinoma.
Oncotarget. 8:98384–98393. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ren JH, He WS, Yan GL, Jin M, Yang KY and
Wu G: EGFR mutations in non-small-cell lung cancer among smokers
and non-smokers: A meta-analysis. Environ Mol Mutagen. 53:78–82.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Jazieh AR, Bounedjar A, Bamefleh H,
Alfayea T, Almaghraby HQ, Belarabi A, Ouahioune W, Derbouz Z,
Alkaiyat M, Alkattan K, et al: Expression of immune response
markers in arab patients with lung cancer. JCO Glob Oncol.
6:1218–1224. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Dietel M, Savelov N, Salanova R, Micke P,
Bigras G, Hida T, Antunez J, Guldhammer Skov B, Hutarew G, Sua LF,
et al: Real-world prevalence of programmed death ligand 1
expression in locally advanced or metastatic non-small-cell lung
cancer: The global, multicenter EXPRESS study. Lung Cancer.
134:174–179. 2019.PubMed/NCBI View Article : Google Scholar
|
